Murphy K, et al. - Researchers performed this open-label extension study to assess safety and efficacy of reslizumab for up to 24 months in patients with eosinophilic asthma. Intravenous reslizumab 3.0 mg/kg displays favorable long-term safety and sustained long-term efficacy in patients with moderate-to-severe eosinophilic asthma. Initial improvements in lung function and asthma control remained for up to 2 years. The long-term safety and efficacy profile of anti-IL-5 strategies was further enhanced with these findings.